Innate Pharma

Regulatory Filings • Sep 17, 2009

INNATE PHARMA ANNOUCES ITS PARTICIPATION TO THE MIDCAP EVENT

September 21 and 22, 2009, Paris, France

• Hervé Brailly, CEO of Innate Pharma, and Stéphane Boissel, Executive Vice President and Chief Financial Officer, will present the Company to the investors
• Upon the occasion of the announcement of interim clinical results for IPH 1101 at the ESMO congress on Monday 21, the Company will host a conference call at 2:30pm on that same day

Marseilles, France, September 17, 2009

Innate Pharma (Euronext Paris: FR0010331421 – IPH) announces today that it will participate to the MidCap Event, a conference dedicated to meetings with companies listed on NYSE-EURONEXT and investors, on September 21 and 22, 2009, in Paris, France.

During this event, Hervé Brailly, CEO of Innate Pharma, and Stéphane Boissel, Executive Vice President and Chief Financial Officer, will meet institutional investors to present Innate Pharma, its development strategy and its latest news.

Furthermore, upon the occasion of the announcement on September 21, 2009, of interim clinical results for IPH 1101, its most advanced drug-candidate at the international ESMO (European Society of Medical Oncology) congress, Innate Pharma will host a conference call on the same day at 2:30 pm (Paris time). Details to connect to this call will be communicated on the Company's website as well as on a Monday press release.

About Innate Pharma:

Innate Pharma S.A. ("the company") is a clinical-stage biopharmaceutical company developing first-in-class immunotherapy drugs for cancer and other severe diseases. The company was incorporated in 1999 and listed on NYSE-Euronext in Paris in 2006.

The company has significant expertise in identifying new targets and bringing novel drug candidates through to clinical proof-of-concept trials. It currently has seven proprietary drug candidates in development (two of which are in Phase II clinical trials) and two programs out-licensed to Novo Nordisk A/S.

Innate Pharma is based in Marseilles, France, and had 86 employees as at June 30, 2009.

Learn more about Innate-Pharma at www.innate-pharma.com.

IPH

Practical Information about Innate Pharma shares:

ISIN code FR0010331421

Ticker code

Disclaimer:

This press release contains certain forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Document de Reference prospectus filed with the AMF, which is available on the AMF website (http://www.amf-france.org) or on Innate Pharma's website.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

For additional information, please contact:

Laure-Hélène Mercier Director, Investor Relations Phone: +33 (0)4 30 30 30 87 Mobile: +33 (0)6 64 18 99 59 investors@innate-pharma.com caroline@alizerp.com

Innate Pharma Alize Public Relations

Caroline Carmagnol Phone: +33 (0)1 41 22 07 31